Aflibercept Biosimilar | C013P

Catalog No.	C013P
Product Name	Aflibercept Biosimilar | C013P
Supplier Name	Syd Labs, Inc.
Brand Name	Syd Labs
Synonyms	Zaltrap Biosimilar, Eylea Biosimilar, ziv-aflibercept, VEGF Receptors 1 and 2 Fc Fusion Protein
Summary	Recombinant protein composed of the binding domains of two human vascular endothelial growth factor (VEGF) receptors fused with the Fc region of human immunoglobulin gamma 1 (hIgG1).
Source/Host	The aflibercept biosimilar protein was produced in the Zaltrap / Eylea biosimilar CHO stable cell line.
Specificity/Sensitivity	The aflibercept biosimilar protein specifically binds to the human VEGF.
Form Of Antibody	0.2 uM filtered solution, pH 6.1, no stabilizers or preservatives.
Endotoxin	<1 EU/mg of the protein by the LAL method.
Purity	>95% by SDS-PAGE under reducing conditions and HPLC.
Shipping	The research grade aflibercept biosimilar protein is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
Note	Zaltrap / Eylea biosimilar CHO stable cell line is available for licensing to manufacture the aflibercept biosimilar protein. The research grade aflibercept biosimilar protein is for research use only (RUO). Recombinant human IgG1 isotype controls and recombinant hIgG1 Fc proteins are available.
Order Offline	Phone: 1-617-401-8149 Fax: 1-617-606-5022 Email: message@sydlabs.com Orleave a message with a formal purchase order (PO) Or credit card.

Description

C013P: Aflibercept Biosimilar

What is research grade Aflibercept biosimilar? Research grade Aflibercept biosimilar has the same amino acid sequence as Aflibercept (trade name Eylea), a recombinant protein composed of the binding domains of two human vascular endothelial growth factor (VEGF) receptors fused with the Fc region of human immunoglobulin gamma 1 (IgG1). It inhibits vascular endothelial growth factor (VEGF), and is used in the treatment of macular edema following Central Retinal Vein Occlusion (CRVO) and neovascular Age-Related Macular Degeneration (AMD). Aflibercept is a dimeric glycoprotein with a molecular weight of 96.9 kilo Daltons (kDa). Glycosylation adds its molecular weight to 115 kDa in total. Ziv-aflibercept (trade name Zaltrap) was developed as an injection for treatment of metastatic colorectal cancer.

Syd Labs also provides the following VEGF-A antibody biosimilar:
Lucentis Biosimilar (Fab produced in E. coli)
Bevacizumab Biosimilar (complete antibody produced in CHO)

Please remember our product information: Aflibercept Biosimilar: C013P Syd Labs

No more offers for this product!